Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 9:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–4 of 4 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: LTP001 Clear all
Terminated Phase 2 Interventional Results available

Study of Efficacy and Safety of LTP001 in Pulmonary Arterial Hypertension

NCT05135000
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
LTP001, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
2
States / cities
Mesa, Arizona • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Sep 4, 2026, 9:09 AM EDT
Terminated Phase 2 Interventional Results available

To Assess the Efficacy of the Investigational Products Compared to Placebo in Participants With IPF

NCT05497284
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
LTP001, Placebo, Standard of Care (SoC)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years to 100 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
2
States / cities
Birmingham, Alabama • Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Sep 4, 2026, 9:09 AM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)

NCT06649110
View directory record Official record
Conditions
Healthy Volunteers, Pulmonary Arterial Hypertension
Interventions
LTP, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
232 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
19
States / cities
Scottsdale, Arizona • Orange, California • Stanford, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Sep 4, 2026, 9:09 AM EDT
Terminated Phase 2 Interventional Results available

Extension Study of Efficacy and Safety of LTP001 in Pulmonary Arterial Hypertension Participants

NCT05764265
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
LTP001
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Mesa, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Sep 4, 2026, 9:09 AM EDT